课题基金 / 基金详情

Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma

Characterization of a novel anti-fibrotic peptide for the treatment of scleroderma
用于治疗硬皮病的新型抗纤维化肽的表征
批准号：
435913
负责人：
Philip Anie
金额：
$59.07万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
未结题
起止时间：
2020-10-01 至 2025-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=435913&lang=en
关键词：
Cd109 Fibrosis Peptide Scleroderma Tgf-Beta

项目摘要

项目成果

Philip Anie的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Scleroderma or systemic sclerosis (scleroderma) is a complex rheumatoid disease that is characterized by defective immune system function, blood vessel damage and scarring (fibrosis) of the skin and internal organs. Fibrosis is a prominent feature of scle
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of CD109 in regulating cellular signaling and responses in skin and oral squamous cell carcinoma cells
Regulation of TGF-beta action in chondrocytes: signaling via ALK1 versus ALK5 pathways
Regulation of TGF-beta action in chondrocytes: signaling via ALK1 versus ALK5 pathways
Skin Repair, Regeneration and Restoration Research Group (SR4G)
海外基金